Obesity Medical Services in China

Obesity is a chronic, relapsing, multifactorial disease characterized by excessive accumulation of body fat that impairs health and increases the risk of comorbidities. Defined clinically as a body mass index (BMI) ≥30 kg/m² in adults, obesity is not merely a cosmetic concern but a systemic endocrine disorder involving dysregulation of appetite control, energy homeostasis, adipokine secretion, insulin sensitivity, and neurohormonal signaling—particularly within the hypothalamus–pituitary–adipose axis. Pathogenesis involves complex interactions among genetic susceptibility (e.g., variants in FTO, MC4R), epigenetic modifications, gut microbiota dysbiosis, environmental drivers (ultra-processed food abundance, sedentary behavior, sleep deprivation, endocrine-disrupting chemicals), and psychosocial factors (chronic stress, depression, food addiction). Globally, obesity prevalence has nearly tripled since 1975: WHO estimates over 650 million adults (13% of the world’s adult population) were obese in 2022, with China reporting a national adult obesity rate of ~16.4% (2023 China Chronic Disease and Risk Factor Surveillance), rising sharply among urban youth and aging populations. Key modifiable risk factors include low physical activity (<150 min/week moderate-intensity exercise), high intake of added sugars and saturated fats, prolonged screen time, shift work, and socioeconomic disadvantage; non-modifiable risks include family history, certain genetic syndromes (e.g., Prader–Willi), and early-life factors (maternal obesity, rapid infant weight gain). Obesity profoundly diminishes quality of life—contributing to mobility limitations, chronic pain (especially knee osteoarthritis), obstructive sleep apnea, social stigma, workplace discrimination, anxiety and depression, reduced sexual function, and diminished self-efficacy. It is a leading preventable cause of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), certain cancers (endometrial, colorectal, postmenopausal breast), and all-cause mortality. Endocrinologists play a central role in diagnosing obesity as a disease—not a lifestyle failure—and managing it through comprehensive, person-centered care that integrates behavioral therapy, pharmacotherapy (e.g., GLP-1 receptor agonists like semaglutide), metabolic surgery evaluation, and longitudinal monitoring of cardiometabolic biomarkers. Early intervention significantly improves long-term outcomes, underscoring the importance of routine BMI screening, waist circumference measurement, and personalized risk stratification in primary and specialty endocrine practice.

Obesity is a complex, chronic, multifactorial disease characterized by excessive adipose tissue accumulation that impairs health. From an endocrinological perspective, it arises from sustained positive energy balance—where caloric intake chronically exceeds energy expenditure—driven by interrelated biological, behavioral, environmental, and genetic determinants. Common causes include dysregulation of central appetite control pathways (e.g., leptin–melanocortin signaling), impaired satiety hormone secretion (e.g., reduced postprandial GLP-1, PYY, and CCK; elevated ghrelin in some phenotypes), and hypothalamic resistance to adiposity signals. Insulin resistance—often preceding overt obesity—promotes lipogenesis, inhibits lipolysis, and contributes to ectopic fat deposition, particularly in visceral, hepatic, and skeletal muscle compartments. Secondary obesity may result from endocrine disorders such as Cushing syndrome (excess glucocorticoids), hypothyroidism (reduced basal metabolic rate), growth hormone deficiency (altered body composition and lipid metabolism), hypothalamic lesions (e.g., craniopharyngioma), and polycystic ovary syndrome (PCOS), where hyperandrogenism and insulin resistance synergistically promote weight gain and abdominal adiposity.

Triggers for weight gain and obesity progression are often context-specific and dynamic. Psychosocial stress activates the hypothalamic–pituitary–adrenal (HPA) axis, increasing cortisol and promoting visceral adiposity and cravings for energy-dense foods. Sleep deprivation disrupts circadian regulation of orexigenic (ghrelin) and anorexigenic (leptin) hormones, elevating hunger and reducing satiety. Certain medications—including glucocorticoids, atypical antipsychotics (e.g., olanzapine, quetiapine), antidepressants (e.g., mirtazapine, paroxetine), beta-blockers, and insulin or sulfonylureas—induce weight gain via metabolic slowing, increased appetite, or enhanced lipogenesis. Perinatal factors also serve as critical triggers: maternal gestational diabetes, excessive gestational weight gain, and infant macrosomia predispose offspring to early-onset obesity through epigenetic programming of metabolic and neuroendocrine pathways.

Genetic factors contribute substantially to obesity susceptibility, with heritability estimates ranging from 40% to 70%. Monogenic forms—though rare—include mutations in LEP (leptin), LEPR (leptin receptor), POMC, PCSK1, and MC4R, all disrupting melanocortin signaling and resulting in severe early-onset obesity, hyperphagia, and endocrine abnormalities (e.g., adrenal insufficiency in POMC deficiency). More commonly, polygenic obesity involves hundreds of common variants identified through genome-wide association studies (GWAS), with FTO (fat mass and obesity-associated gene) being the strongest known locus; risk alleles modulate hypothalamic responsiveness to food cues and impair satiety perception. Epigenetic modifications—DNA methylation, histone modification, and non-coding RNA expression—mediate gene–environment interactions, especially during developmental windows.

Environmental factors constitute the predominant drivers of the global obesity epidemic. Ubiquitous access to ultra-processed, high-calorie, low-nutrient foods—characterized by added sugars (especially fructose), refined carbohydrates, and saturated/trans fats—disrupts homeostatic feeding regulation and promotes hedonic overeating. Sedentary behavior, including prolonged screen time and occupational inactivity, markedly reduces non-exercise activity thermogenesis (NEAT) and overall energy expenditure. Built environment features—such as lack of safe sidewalks, limited green space, car-dependent urban design, and food deserts (areas with poor access to affordable, nutritious foods)—systematically constrain healthy lifestyle choices. Socioeconomic status (SES) strongly correlates with obesity prevalence: lower SES is associated with higher exposure to obesogenic environments, greater psychosocial stress, reduced health literacy, limited access to preventive care and nutrition counseling, and increased reliance on inexpensive, energy-dense foods. Additionally, endocrine-disrupting chemicals (EDCs)—including bisphenol A, phthalates, and persistent organic pollutants—may act as 'obesogens' by altering adipocyte differentiation, lipid metabolism, and hypothalamic appetite regulation. Collectively, these factors interact across the life course, reinforcing pathophysiological loops that render obesity biologically entrenched and clinically refractory without comprehensive, individualized, multidisciplinary intervention.

Obesity is a chronic, relapsing, multifactorial disease characterized by excessive adipose tissue accumulation that impairs health. In the Department of Endocrinology, obesity is evaluated not merely as a cosmetic concern but as a systemic endocrine-metabolic disorder with profound implications for hormonal regulation, insulin sensitivity, inflammation, and organ function. Early symptoms are often subtle and nonspecific, reflecting initial metabolic decompensation rather than overt pathology. Patients may report persistent fatigue disproportionate to activity level, mild exertional dyspnea during routine tasks (e.g., climbing one flight of stairs), increased daytime somnolence despite adequate sleep duration, and gradual reduction in physical endurance. Subtle endocrine manifestations include menstrual irregularities in premenopausal women—such as oligomenorrhea or secondary amenorrhea—often linked to hyperandrogenism and polycystic ovary syndrome (PCOS). Men may experience decreased libido, erectile dysfunction, or reduced morning testosterone levels. Mild, asymptomatic elevations in fasting glucose or HbA1c may be detected incidentally on routine screening, signaling early insulin resistance. Sleep disturbances—including fragmented sleep and unrefreshing rest—are common precursors to obstructive sleep apnea, though formal diagnosis typically follows later.

Typical symptoms emerge as adiposity increases and physiological strain intensifies. Dyspnea on exertion becomes more pronounced and reproducible; orthopnea may develop in severe cases. Joint pain—particularly in weight-bearing articulations such as knees, hips, and lumbar spine—is frequent, often described as deep, aching, and aggravated by prolonged standing or ambulation. Patients commonly report chronic low back pain due to mechanical overload and altered biomechanics. Gastroesophageal reflux disease (GERD) manifests as recurrent heartburn, regurgitation, or nocturnal cough, driven by increased intra-abdominal pressure and transient lower esophageal sphincter relaxation. Skin changes become evident: acanthosis nigricans (velvety, hyperpigmented plaques in intertriginous areas such as neck, axillae, and groin) reflects severe insulin resistance; striae distensae (wide, violaceous stretch marks) appear on abdomen, thighs, and breasts; intertrigo—erythematous, macerated, pruritic lesions in skin folds—may become secondarily infected with Candida or bacteria. Edema of the lower extremities can occur secondary to venous insufficiency or right heart strain.

Accompanying symptoms reflect multisystem involvement. Cognitive complaints—including brain fog, impaired concentration, and slowed processing speed—are increasingly recognized as correlates of systemic inflammation and adipokine dysregulation. Mood disturbances such as low-grade depression, anhedonia, and social withdrawal are prevalent and bidirectionally linked to neuroendocrine alterations (e.g., hypothalamic-pituitary-adrenal axis dysregulation, reduced BDNF). Patients frequently describe heat intolerance and increased sweating due to elevated basal metabolic demand and impaired thermoregulation. Urinary symptoms—including urinary frequency, urgency, and stress incontinence—arise from pelvic floor weakness and elevated intra-abdominal pressure. Headaches, particularly tension-type or migraine variants, may worsen due to chronic low-grade inflammation and comorbid hypertension or sleep-disordered breathing.

Complications constitute the primary clinical burden and drive morbidity and mortality. Metabolic complications include type 2 diabetes mellitus (T2DM), prediabetes, dyslipidemia (elevated triglycerides, low HDL-C, small dense LDL particles), and nonalcoholic fatty liver disease (NAFLD), which may progress to steatohepatitis (NASH), fibrosis, and cirrhosis. Cardiovascular sequelae encompass hypertension (often salt-sensitive and resistant), left ventricular hypertrophy, diastolic dysfunction, coronary artery disease, atrial fibrillation, and heart failure with preserved ejection fraction (HFpEF). Respiratory complications include obstructive sleep apnea (OSA)—with associated hypoxemia, sympathetic overactivity, and pulmonary hypertension—and obesity hypoventilation syndrome (OHS), marked by chronic hypercapnia and respiratory acidosis. Endocrine complications extend beyond PCOS and hypogonadism to include subclinical or overt thyroid dysfunction (elevated TSH with normal T4, often reflecting leptin-mediated central modulation), and increased risk of certain malignancies (e.g., endometrial, postmenopausal breast, colorectal, esophageal adenocarcinoma) mediated by chronic inflammation, sex hormone excess, and insulin/IGF-1 signaling. Musculoskeletal complications include osteoarthritis (accelerated joint degeneration), gout (hyperuricemia), and idiopathic intracranial hypertension (pseudotumor cerebri), presenting with headache, pulsatile tinnitus, and visual obscurations.

Diagnosis relies on integrated assessment. Body mass index (BMI) remains the cornerstone metric: ≥30 kg/m² defines obesity; ≥35 kg/m² with comorbidity or ≥40 kg/m² indicates severe obesity warranting intensive intervention. However, BMI alone is insufficient; waist circumference (>102 cm in men, >88 cm in women) and waist-to-hip ratio (>0.95 in men, >0.85 in women) assess abdominal adiposity and cardiometabolic risk. Dual-energy X-ray absorptiometry (DXA), air displacement plethysmography (Bod Pod), or MRI-based fat quantification provide precise adipose distribution data but are reserved for research or complex cases. Laboratory evaluation includes fasting glucose, HbA1c, lipid panel, liver enzymes (ALT, AST, GGT), serum creatinine/eGFR, thyroid-stimulating hormone (TSH), testosterone (total and free in symptomatic individuals), and inflammatory markers (e.g., hs-CRP). Polysomnography is indicated for suspected OSA; echocardiography for suspected cardiac structural or functional abnormalities; and upper endoscopy or hepatic elastography for advanced NAFLD/NASH evaluation.

Differential diagnosis is essential to exclude secondary causes, particularly in patients with rapid weight gain, atypical fat distribution, or endocrine stigmata. Cushing syndrome must be distinguished by features including proximal muscle weakness, purple striae (>1 cm wide), easy bruising, facial plethora, and supraclavicular fat pads; confirmed via late-night salivary cortisol, dexamethasone suppression testing, and ACTH measurement. Hypothyroidism presents with fatigue, cold intolerance, constipation, dry skin, and bradycardia—but rarely causes BMI >35 without other etiologies; TSH and free T4 differentiate it. Growth hormone deficiency in adults may cause increased truncal fat and decreased lean mass but is accompanied by dyslipidemia, insulin resistance, and low IGF-1. Prader-Willi syndrome manifests in childhood with neonatal hypotonia, hyperphagia, developmental delay, and characteristic facies; genetic testing confirms diagnosis. Medication-induced weight gain (e.g., glucocorticoids, antipsychotics, antidepressants, insulin, sulfonylureas) requires careful medication review. Rare genetic obesities (e.g., MC4R deficiency, leptin deficiency) present with early-onset, severe obesity and intense hunger; leptin levels and genetic panels guide identification. Finally, depression and binge-eating disorder require psychiatric evaluation, as behavioral drivers significantly influence treatment trajectory and outcomes.

Obesity is a chronic, relapsing, multifactorial disease characterized by excessive adipose tissue accumulation that impairs health and increases the risk of cardiovascular disease, type 2 diabetes mellitus (T2DM), obstructive sleep apnea, osteoarthritis, nonalcoholic fatty liver disease (NAFLD), and multiple malignancies. In the Department of Endocrinology, obesity management follows an evidence-based, patient-centered, staged approach aligned with international guidelines (e.g., ADA, EASO, AACE) and adapted to China’s epidemiological and healthcare context.

Conservative treatment remains the cornerstone of obesity management and should be initiated for all patients, regardless of BMI category or comorbidity burden. It comprises three interdependent pillars: medical nutrition therapy (MNT), structured physical activity, and behavioral interventions. MNT emphasizes energy deficit (typically 500–750 kcal/day reduction), high-protein (1.2–1.5 g/kg ideal body weight/day), moderate-carbohydrate (45–55% of total calories), low-glycemic-index diets rich in fiber and unsaturated fats. Meal timing strategies—including time-restricted eating (e.g., 12- to 14-hour overnight fast)—are increasingly supported by metabolic data. Physical activity prescriptions target ≥150 minutes/week of moderate-intensity aerobic exercise (e.g., brisk walking, cycling) plus two weekly sessions of resistance training to preserve lean mass and improve insulin sensitivity. Behavioral interventions—delivered via individual counseling, group programs, or digital therapeutics—focus on self-monitoring (food/activity logs), stimulus control, cognitive restructuring, goal setting, and relapse prevention. In China, culturally tailored adaptations include integration of traditional dietary patterns (e.g., emphasis on vegetables, legumes, whole grains; reduced refined carbohydrates and cooking oil), promotion of tai chi and qigong as sustainable low-impact modalities, and family-involved education given the strong influence of household eating habits.

Pharmacotherapy is indicated for adults with BMI ≥30 kg/m² or ≥25 kg/m² with at least one obesity-related comorbidity (e.g., hypertension, dyslipidemia, T2DM, NAFLD) who have not achieved ≥5% weight loss after 3–6 months of intensive lifestyle intervention. First-line agents in China include GLP-1 receptor agonists (GLP-1 RAs): semaglutide (2.4 mg subcutaneous weekly) and tirzepatide (a dual GIP/GLP-1 RA, recently approved). These agents promote satiety, delay gastric emptying, and enhance glucose-dependent insulin secretion, yielding mean weight losses of 15–22% over 68 weeks in pivotal trials. Liraglutide (3.0 mg daily) remains widely used, particularly where cost constraints exist. Orlistat (120 mg three times daily) inhibits pancreatic and gastric lipases, reducing fat absorption by ~30%; it is accessible and reimbursed under China’s National Reimbursement Drug List (NRDL), though gastrointestinal side effects limit adherence. Emerging agents—such as retatrutide (triple agonist) and cagrilintide (amylin analog)—are under clinical evaluation in Chinese Phase III trials. All pharmacotherapies require ongoing monitoring of efficacy (weight trajectory, waist circumference, HbA1c, liver enzymes), safety (pancreatitis, gallstones, psychiatric symptoms), and renal function. Contraindications include personal/family history of medullary thyroid carcinoma or MEN2 syndrome for GLP-1 RAs.

Bariatric-metabolic surgery is recommended for adults with BMI ≥37.5 kg/m² or ≥32.5 kg/m² with significant comorbidities refractory to medical therapy. Common procedures performed in Chinese endocrine centers include laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass (RYGB). LSG—accounting for >85% of bariatric surgeries in China—is technically less complex, associated with lower perioperative morbidity, and achieves 25–35% total body weight loss (TBWL) at 2 years, with durable remission of T2DM (>60%), hypertension (>50%), and obstructive sleep apnea (>75%). RYGB offers superior glycemic control and greater weight loss but carries higher nutritional risks (e.g., iron, B12, calcium deficiency) requiring lifelong supplementation and surveillance. Endoscopic bariatric therapies—including intragastric balloon (6-month placement) and endoscopic sleeve gastroplasty (ESG)—serve as bridge options for high-risk surgical candidates or those seeking minimally invasive alternatives; ESG yields ~15–20% TBWL at 12 months with favorable safety profiles. All surgical candidates undergo comprehensive preoperative assessment: psychological evaluation, nutritional status (vitamin D, ferritin, albumin), cardiopulmonary testing, and multidisciplinary review involving endocrinology, surgery, nutrition, and psychiatry.

Treatment advantages in China stem from integrated care models, rapid adoption of novel therapeutics, and robust public health infrastructure. The National Health Commission’s ‘Healthy China 2030’ initiative prioritizes obesity prevention through school-based nutrition policies, urban green space expansion, and workplace wellness programs. Endocrinology departments in tier-1 hospitals (e.g., Peking Union Medical College Hospital, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital) operate dedicated Obesity Management Centers offering longitudinal, team-based care with standardized protocols, electronic health record–integrated decision support, and telehealth follow-up. China’s regulatory pathway enables faster approval of innovative agents—semaglutide and tirzepatide gained NMPA approval within 12 months of FDA clearance—and broad NRDL coverage improves affordability. Moreover, large-scale real-world evidence studies (e.g., the China Obesity Cohort) inform local practice guidelines and optimize risk stratification using region-specific cutoffs (e.g., BMI ≥24 kg/m² for overweight, ≥28 kg/m² for obesity in Asian populations).

Post-treatment recovery requires lifelong commitment. Patients undergoing lifestyle intervention should schedule quarterly visits for anthropometric reassessment, metabolic panel review, and motivational interviewing. Those on pharmacotherapy need monthly evaluations during dose escalation, then biannual assessments once stable. Surgical patients require mandatory follow-up at 1, 3, 6, and 12 months postoperatively, then annually: monitoring includes micronutrient panels, bone density (DEXA) every 2 years, and screening for dumping syndrome or weight regain. Nutritional rehabilitation emphasizes protein-first meals, vitamin/mineral supplementation (e.g., multivitamin with iron, B12, calcium, vitamin D), and avoidance of liquid calories and high-sugar foods. Psychological support—including cognitive-behavioral therapy and peer support groups—is critical to sustain behavior change and address emotional eating. Long-term success correlates strongly with consistent self-monitoring, social accountability, and early re-engagement upon weight plateau or regain. In summary, optimal obesity management in endocrinology demands a continuum of care—from prevention and conservative strategies to advanced pharmacotherapy and surgery—delivered with cultural competence, technological enablement, and unwavering patient partnership.